Click here to view online. Add this email to your safelist.

AstraZeneca logo

Calquence shows long-term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma

6 December 2020

Long-term follow-up results from the positive ACE-LY-004 Phase II trial showed patients with relapsed or refractory mantle cell lymphoma (MCL) treated with Calquence (acalabrutinib) remained progression free for a median of 22 months, with median overall survival not yet reached at three years of follow-up. The safety and tolerability profile remained consistent.1 These results were presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition on 6 December 2020.

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2020

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.